ALK

4 registered clinical trials studyying ALK — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib NCT07374614	Peking University Shenzhen Hospital	—
Not Yet Recruiting	Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC NCT07235306	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Not Yet Recruiting	The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Ris NCT06772610	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Not Yet Recruiting	The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-pos NCT06652555	Shanghai Pulmonary Hospital, Shanghai, China	—